[go: up one dir, main page]

MXPA04001525A - Analogos de peptido -1 similar al glucagon. - Google Patents

Analogos de peptido -1 similar al glucagon.

Info

Publication number
MXPA04001525A
MXPA04001525A MXPA04001525A MXPA04001525A MXPA04001525A MX PA04001525 A MXPA04001525 A MX PA04001525A MX PA04001525 A MXPA04001525 A MX PA04001525A MX PA04001525 A MXPA04001525 A MX PA04001525A MX PA04001525 A MXPA04001525 A MX PA04001525A
Authority
MX
Mexico
Prior art keywords
glucagon
peptide
analogs
glp
compounds
Prior art date
Application number
MXPA04001525A
Other languages
English (en)
Inventor
Glaesner Wolfgang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MXPA04001525A publication Critical patent/MXPA04001525A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describe compuestos de peptido-1 de tipo glucagon GLP-1 con modificaciones en una o mas de las siguientes posiciones:7, 8, 12, 16, 18, 19, 20, 22, 25, 27, 30, 33 y 37. Se describen tambien procedimientos para el tratamiento de un sujeto que necesita la estimulacion del receptor de GLP-1 usando estos compuestos de GLP-1.
MXPA04001525A 2001-08-23 2002-08-14 Analogos de peptido -1 similar al glucagon. MXPA04001525A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31457301P 2001-08-23 2001-08-23
PCT/US2002/021325 WO2003018516A2 (en) 2001-08-23 2002-08-14 Glucagon-like peptide-1 analogs

Publications (1)

Publication Number Publication Date
MXPA04001525A true MXPA04001525A (es) 2004-05-31

Family

ID=23220481

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001525A MXPA04001525A (es) 2001-08-23 2002-08-14 Analogos de peptido -1 similar al glucagon.

Country Status (11)

Country Link
US (1) US7101843B2 (es)
EP (1) EP1432730A4 (es)
JP (1) JP4227894B2 (es)
KR (1) KR100593348B1 (es)
AU (1) AU2002322403A1 (es)
BR (1) BR0212080A (es)
CA (1) CA2458371A1 (es)
HU (1) HUP0501192A3 (es)
IL (1) IL160493A0 (es)
MX (1) MXPA04001525A (es)
WO (1) WO2003018516A2 (es)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO2001077137A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
ES2569916T3 (es) 1999-06-29 2016-05-13 Mannkind Corporation Formulaciones farmacéuticas que comprenden insulina complejada con una dicetopiperazina
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
EP2277889B1 (en) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
DE60335608D1 (de) * 2002-02-27 2011-02-17 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
ES2425392T3 (es) 2002-03-20 2013-10-15 Mannkind Corporation Cartucho para un aparato de inhalación
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
PT1605897E (pt) 2003-03-19 2012-09-10 Lilly Co Eli Compostos de glp-1 ligado a polietilenoglicol
ATE549028T1 (de) 2003-05-15 2012-03-15 Tufts College Stabile analoga von glp-1
KR101308912B1 (ko) 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
ES2375056T3 (es) 2003-06-03 2012-02-24 Novo Nordisk A/S Composiciones pept�?dicas farmacéuticas estabilizadas.
CA2552526A1 (en) 2004-01-08 2005-07-21 Theratechnologies Inc. Glucagon-like peptide-1 analogs with long duration of action
CA2554089C (en) 2004-02-09 2013-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005112977A2 (en) * 2004-04-23 2005-12-01 Pharmain, Ltd. Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US20060266406A1 (en) * 2004-06-09 2006-11-30 Tom Faust Devulcanized photovoltaic roofing tiles
ES2385934T3 (es) 2004-08-20 2012-08-03 Mannkind Corporation Catálisis de la síntesis de dicetopiperazina.
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
DK1888103T3 (da) * 2005-04-11 2012-04-23 Amylin Pharmaceuticals Inc Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering
US7799344B2 (en) 2005-09-14 2010-09-21 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
WO2007049695A1 (ja) * 2005-10-26 2007-05-03 Chugai Seiyaku Kabushiki Kaisha 凝集性ｇｌｐ－１アナログおよび徐放性医薬組成物
HRP20160866T1 (hr) * 2005-11-04 2016-10-07 Glaxosmithkline Llc Postupci primjene hipoglikemijskih sredstava
WO2007053946A1 (en) 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
CA2633070C (en) 2005-12-19 2016-03-08 Pharmain Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
EP1971355B1 (en) 2005-12-20 2020-03-11 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) * 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8039431B2 (en) 2006-02-22 2011-10-18 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
MX2008013304A (es) 2006-04-20 2008-10-27 Amgen Inc Compuestos de peptido 1 tipo glucagon.
JP5143131B2 (ja) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
PE20080840A1 (es) * 2006-09-13 2008-08-27 Smithkline Beecham Corp Metodos para administrar agentes hipoglucemiantes de larga duracion
CN101715340A (zh) 2007-04-23 2010-05-26 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
EP2185178B1 (en) 2007-08-03 2017-08-23 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
BRPI0818874A2 (pt) * 2007-10-24 2015-05-05 Mannkind Corp Liberação de agentes ativos
CA2703338A1 (en) * 2007-10-24 2009-04-30 Mannkind Corporation Method of preventing adverse effects by glp-1
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
CA2724534A1 (en) * 2008-05-14 2009-11-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of somatostatin-dopamine conjugates
DK2293833T3 (en) 2008-06-13 2016-05-23 Mannkind Corp DRY POWDER INHALER AND MEDICINAL ADMINISTRATION SYSTEM
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
JP5479465B2 (ja) 2008-06-20 2014-04-23 マンカインド コーポレイション 吸入努力をリアルタイムにプロファイルする対話式機器および方法
WO2009158704A2 (en) 2008-06-27 2009-12-30 Duke University Therapeutic agents comprising elastin-like peptides
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
ES2614427T3 (es) 2008-11-07 2017-05-31 The General Hospital Corporation Fragmentos C-terminales de péptido glucagonoide 1 (GLP-1)
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US8551528B2 (en) 2009-06-12 2013-10-08 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
PL3311828T3 (pl) * 2009-08-14 2021-11-22 Phasebio Pharmaceuticals, Inc. Zmodyfikowane wazoaktywne peptydy jelitowe
KR102093612B1 (ko) 2009-09-28 2020-03-26 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
US9016147B2 (en) 2009-11-03 2015-04-28 Mannkind Corporation Apparatus and method for simulating inhalation efforts
WO2011136361A1 (ja) 2010-04-30 2011-11-03 株式会社 三和化学研究所 生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質
ES2661228T3 (es) 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
IL223742A (en) 2010-06-21 2016-06-30 Mannkind Corp A dry powder inhaler and preparation for it
CA2796894A1 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
AU2011274229A1 (en) 2010-07-02 2013-01-10 Angiochem Inc. Short and D-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
WO2012061466A2 (en) 2010-11-02 2012-05-10 The General Hospital Corporation Methods for treating steatotic disease
JP2014502985A (ja) * 2011-01-19 2014-02-06 ノヴォ ノルディスク アー／エス Ｇｌｐ−１粒子および組成物
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
MY180552A (en) 2011-04-01 2020-12-02 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012170524A1 (en) 2011-06-06 2012-12-13 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
EP2729157B1 (en) 2011-07-06 2019-01-16 The General Hospital Corporation A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
EP2776053A1 (en) 2011-10-24 2014-09-17 MannKind Corporation Methods and compositions for treating pain
HK1198810A1 (en) 2011-11-17 2015-06-12 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
SG11201500218VA (en) 2012-07-12 2015-03-30 Mannkind Corp Dry powder drug delivery systems and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
TWI523863B (zh) 2012-11-01 2016-03-01 艾普森藥品公司 體抑素－多巴胺嵌合體類似物
HK1213486A1 (zh) 2012-11-01 2016-07-08 Ipsen Pharma S.A.S. 促生长素抑制素类似物及其二聚体
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
MX394255B (es) 2013-07-18 2025-03-24 Mannkind Corp Composiciones farmaceuticas en polvo seco estables al calor y metodos
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US10626156B2 (en) 2013-12-06 2020-04-21 Jie Han Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
AU2015255752B2 (en) 2014-05-08 2020-07-23 Immunoforge Co., Ltd. Methods and compositions for treating Cystic Fibrosis
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
JP6824888B2 (ja) 2015-02-09 2021-02-03 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 筋肉の疾患および障害を治療するための方法および組成物
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
EP3463413A4 (en) * 2016-05-25 2020-03-04 Merck Sharp & Dohme Corp. INSULIN RECEPTOR PART AGONISTS
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CA3049034A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
IL320142A (en) 2018-10-11 2025-06-01 Intarcia Therapeutics Inc Human amylin analog polypeptides and methods of use
US20240374690A1 (en) 2021-01-25 2024-11-14 Mylan Ireland Limited Pharmaceutical Peptide Compositions and Methods of Preparation Thereof
IL309341A (en) * 2021-06-14 2024-02-01 Darbix Llc GLP-1 receptor agonists with improved pharmacological properties and drug delivery
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2025015283A1 (en) * 2023-07-13 2025-01-16 The Penn State Research Foundation Opioid use disorder combination treatments

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
DE69916811T2 (de) 1998-02-27 2005-04-14 Novo Nordisk A/S Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
EP1062240B1 (en) * 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminally modified glp-1 derivatives
DE69942306D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As Abkömmlinge von glp-1 analogen
DE69911975T2 (de) * 1998-07-31 2004-09-09 Novo Nordisk A/S In-vitro stimulation von beta zellen vermehrung
CA2361830A1 (en) 1999-03-17 2000-09-21 Novo Nordisk A/S Method for acylating peptides and novel acylating agents
JP4716641B2 (ja) * 2000-06-16 2011-07-06 イーライ リリー アンド カンパニー グルカゴン様ペプチド−１類似体
BR0116024A (pt) * 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma

Also Published As

Publication number Publication date
JP2005528321A (ja) 2005-09-22
IL160493A0 (en) 2004-07-25
KR100593348B1 (ko) 2006-06-26
CA2458371A1 (en) 2003-03-06
HUP0501192A2 (en) 2006-03-28
AU2002322403A1 (en) 2003-03-10
EP1432730A4 (en) 2006-10-11
US7101843B2 (en) 2006-09-05
HUP0501192A3 (en) 2006-06-28
WO2003018516A3 (en) 2004-02-26
EP1432730A2 (en) 2004-06-30
KR20040039302A (ko) 2004-05-10
WO2003018516A2 (en) 2003-03-06
JP4227894B2 (ja) 2009-02-18
BR0212080A (pt) 2006-04-04
US20040198654A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
MXPA04001525A (es) Analogos de peptido -1 similar al glucagon.
MY137350A (en) Glucagon-like peptide-1 analogs
AU2002213925A1 (en) Use of glp-1 and flp-2 peptides for treatment of bone disorders
ZA9811466B (en) Glucagon-like peptide-1 crystals.
AU2003239478A8 (en) Modified glucagon-like peptide-1 analogs
AU5984801A (en) Local anesthetic methods and kits
EA200401345A1 (ru) Лечение гастропареза
ZA200110408B (en) Methods for treating diabetes.
MXPA03011306A (es) Metodos para la preparacion y uso de 1a,24 (s) - hidroxivitamina d2.
AU2003252182A8 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
WO1999053064A3 (en) Methods of delivering glp-1
IL131478A0 (en) Methods for treatment of scar tissue
UA88862C2 (en) Glucagon-like peptide-1 analogs
WO2003003971A3 (fr) Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant
MXPA03006157A (es) Metodo de terapia de reemplazo de hormona y su forma de administracion.
Manukhin On using the power cross section of elastic interaction; K voprosu ob ispol'zovanii stepennogo secheniya uprugogo vzaimodejstviya
SV2002000484A (es) Analogos del peptido-1 semejante a glucacon ref. x-13989
ZA200007258B (en) Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal